Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

ATP-Triggered Nanoparticles Effectively Kill Breast Cancer Cells in Mouse Model

By BiotechDaily International staff writers
Posted on 25 Mar 2014
Print article
Image: The structure of the ATP-triggered nanoparticle (left) and how the nanoparticles shrink a tumor (right) (Photo courtesy of North Carolina State University).
Image: The structure of the ATP-triggered nanoparticle (left) and how the nanoparticles shrink a tumor (right) (Photo courtesy of North Carolina State University).
A recent paper describes novel nanoparticles that transport toxic anticancer drugs specifically to tumor cells where they are engulfed and induced to release their cargo by the high intracellular concentration of adenosine-5'-triphosphate (ATP).

The nanoparticles, which were composed of a liposomal core enclosed in a cross-linked hyaluronic acid (HA)-based gel shell (designated Gelipo), were devised by a team of investigators at North Carolina State University (Raleigh, USA) and the University of North Carolina (Chapel Hill, USA). The cores of the nanoparticles were loaded with an ATP-binding aptamer-incorporated DNA motif that was able to selectively release incorporated molecules of the cancer drug doxorubicin (Dox) via a conformational switch when in an ATP-rich environment. Aptamers are nucleic acid species that have been engineered through repeated rounds of in vitro selection to bind to various molecular targets such as small molecules, proteins, and nucleic acids.

The nanoparticles were tested on a mouse cancer model. Following injection of the nanoparticles into mice carrying the MDA-MB-231 xenograft tumor, the HA shells were degraded by hyaluronidase (HAase) enzyme that was concentrated in the tumor environment. This resulted in the rapid internalization of the liposomes, which, in turn, caused release of the aptamer-DNA-Dox molecules into the tumor cells. The high concentration of ATP inside the tumor cells then caused the aptamer-DNA molecules to unfold and release the Dox, which killed the cells.

Results reported in the March 11, 2014, online edition of the journal Nature Communications showed that the new type of nanoparticles were 3.6 times more effective against MDA-MB-231 human breast cancer cells than previously tested nanoparticles that did not incorporate an ATP-triggered component.

"This is a proof of concept, but we have demonstrated there is now a new tool for introducing anti-cancer drugs directly into cancer cells—and that should make drug treatments significantly more effective," said senior author Dr. Zhen Gu, assistant professor in the joint biomedical engineering program at North Carolina State University and the University of North Carolina. "We also believe that we will be able to make the technique even more targeted by manipulating ATP levels in specific areas."

Related Links:

North Carolina State University
University of North Carolina



Print article

Channels

Genomics/Proteomics

view channel
Image: Healthy blood cells along with sickle-cell diseased cells (Photo courtesy of Science Picture Co./Corbis).

Gene Editing Corrects Hemoglobin Defects in Beta-Thalassemia and Sickle Cell Disease

A team of hematology researchers used the CRISPR/Cas9 gene editing technique to correct the mutations that cause defective blood cell morphology in beta-thalassemia and sickle cell disease.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.